CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 290 enrolled
Drug / intervention
Methoxy-polyethyleneglycol epoetin betadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02538107
NCT02538107N/ACompleted
CompareCT.gov

Non-interventional, Observational Study to Investigate the Efficiency and Safety of Mircera in Patients With a Kidney Transplant

Hoffmann-La Roche·observational·Posted Sep 2, 2015·Updated Jun 7, 2017

In Brief

An observational study evaluating Methoxy-polyethyleneglycol epoetin beta for Anemia, Kidney Transplantation. Completed, enrolled 290 participants across 1 site.

Detailed Summary

This observational study will investigate efficacy and safety of methoxy polyethyleneglycol-epoetin beta in participants with a kidney transplant. Data of each participant will be collected over 15 months of Mircera therapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Kidney Transplantation
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2, 2015
Enrollment StartSep 30, 2007
Primary CompletionNov 30, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.8 years ago

Interventions

Methoxy-polyethyleneglycol epoetin betadrug